• PDF: Delivered by email usually within 12 to 24 UK business hours.

Chinese University of Hong Kong - Developmental Therapeutics Review
Q1 2011

Chinese University of Hong Kong - Developmental Therapeutics Review Q1 2011

Chinese University of Hong Kong - Developmental Therapeutics Review - Q1 2011

Summary

Global Market Direct's pharmaceuticals report, ""Chinese University of Hong Kong - Developmental Therapeutics Review - Q1 2011"" provides data on the institute's research and development focus. The report includes information on therapeutics under development, complete with latest updates, and features on discontinued projects (if applicable).
This report is built using data and information sourced from Global Markets Direct's proprietary databases, institute's website, and featured press releases, both from institute and industry-specific third party sources, put together by Global Markets Direct's team of industry experts.

Scope

  • Review of therapeutics under development by Chinese University of Hong Kong.
  • Overview of products under development across various therapy areas.
  • Coverage of therapeutic molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Chinese University of Hong Kong with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of Chinese University of Hong Kong's therapeutic products in the last quarter.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify new drug targets and therapeutic classes in Chinese University of Hong Kong's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying opportunities to fill portfolio gaps.
  • Evaluate Chinese University of Hong Kong's position with total access to a detailed information on its therapeutic products development.
  • Assess the growth potential of Chinese University of Hong Kong in its therapy areas of focus.
  • Exploit collaboration and partnership opportunities with Chinese University of Hong Kong.
  • Avoid Intellectual Property Rights related issues.
  • Chinese University of Hong Kong Snapshot
    • Chinese University of Hong Kong Overview
    • Key Information
    • Key Facts
    • Chinese University of Hong Kong - Research and Development Overview
    • Key Therapeutic Areas
    • Chinese University of Hong Kong - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Chinese University of Hong Kong - Pipeline Products Glance
    • Chinese University of Hong Kong - Late Stage Pipeline
    • Phase III Products/Combination Treatment Modalities
    • Chinese University of Hong Kong Clinical Stage Pipeline Products
    • Phase II Products/Combination Treatment Modalities
    • Chinese University of Hong Kong - Drug Profiles
    • Aliskiren
    • Product Description
    • Mechanism of Action
    • R&D Progress
    • Celecoxib
    • Product Description
    • Mechanism of Action
    • R&D Progress
    • Celecoxib + Famotidine
    • Product Description
    • Mechanism of Action
    • R&D Progress
    • Fosamax
    • Product Description
    • Mechanism of Action
    • R&D Progress
    • Gemcitabine + Cisplatin for Nasopharyngeal Carcinoma (Chinese University of Hong Kong)
    • Product Description
    • Mechanism of Action
    • R&D Progress
    • Imipramine
    • Product Description
    • Mechanism of Action
    • R&D Progress
    • Magnesium Sulfate
    • Product Description
    • Mechanism of Action
    • R&D Progress
    • Naproxen
    • Product Description
    • Mechanism of Action
    • R&D Progress
    • Nexium
    • Product Description
    • Mechanism of Action
    • R&D Progress
    • Omeprazole
    • Product Description
    • Mechanism of Action
    • R&D Progress
    • Rabeprazole
    • Product Description
    • Mechanism of Action
    • R&D Progress
    • Ramipril
    • Product Description
    • Mechanism of Action
    • R&D Progress
    • Simvastatin for Aneurysmal Subarachnoid Haemorrhage (Chinese University of Hong Kong)
    • Product Description
    • Mechanism of Action
    • R&D Progress
    • Zanamivir
    • Product Description
    • Mechanism of Action
    • R&D Progress
    • Axitinib
    • Product Description
    • Mechanism of Action
    • R&D Progress
    • CUF2
    • Product Description
    • Mechanism of Action
    • R&D Progress
    • Curcumin + Ginkgo Extract
    • Product Description
    • Mechanism of Action
    • R&D Progress
    • Danggui Buxue Tang
    • Product Description
    • Mechanism of Action
    • R&D Progress
    • Danshen + Gegen
    • Product Description
    • Mechanism of Action
    • R&D Progress
    • Lingzhi + Sen Miao San
    • Product Description
    • Mechanism of Action
    • R&D Progress
    • Methotrexate + Infliximab
    • Product Description
    • Mechanism of Action
    • R&D Progress
    • Methotrexate + Infliximab
    • Product Description
    • Mechanism of Action
    • R&D Progress
    • Nexium
    • Product Description
    • Mechanism of Action
    • R&D Progress
    • Paracetamol + Ibuprofen
    • Product Description
    • Mechanism of Action
    • R&D Progress
    • Pegylated Interferon + Lamivudine
    • Product Description
    • Mechanism of Action
    • R&D Progress
    • Recombinant Epstein-Barr Virus (EBV) Vaccine
    • Product Description
    • Mechanism of Action
    • R&D Progress
    • Rituximab
    • Product Description
    • Mechanism of Action
    • R&D Progress
    • Rituximab + Cyclophosphamide
    • Product Description
    • Mechanism of Action
    • R&D Progress
    • Rosuvastatin
    • Product Description
    • Mechanism of Action
    • R&D Progress
    • Shi-Bi-Lin
    • Product Description
    • Mechanism of Action
    • R&D Progress
    • Traditional Chinese Medicine
    • Product Description
    • Mechanism of Action
    • R&D Progress
    • Chinese University of Hong Kong - Pipeline Analysis
    • Chinese University of Hong Kong - Pipeline Products by Therapeutic Class
    • Chinese University of Hong Kong - Pipeline Products By Target
    • Chinese University of Hong Kong - Pipeline Products by Route of Administration
    • Chinese University of Hong Kong - Pipeline Products by Molecule Type
    • Chinese University of Hong Kong - Dormant Projects
    • Chinese University of Hong Kong - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
    • Paricalcitol
    • Chinese University of Hong Kong - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
    • Recent Developments
    • Jan 15, 2009: Traditional Chinese Medicine Effectively Relieves Irritable Bowel Syndrome
    • Feb 04, 2004: NIH Grants Bring CUHK's Research On Chinese Medicine To The International Arena
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer
  • List of Tables
    • Chinese University of Hong Kong - Pipeline by Therapy Area and Indication, 2011
    • Chinese University of Hong Kong - Pipeline by Stage of Development, 2011
    • Chinese University of Hong Kong - Monotherapy Products in Pipeline, 2011
    • Chinese University of Hong Kong - Combination Treatment Modalities in Pipeline, 2011
    • Chinese University of Hong Kong - Phase III, 2011
    • Chinese University of Hong Kong - Phase II, 2011
    • Chinese University of Hong Kong - Pipeline By Therapeutic Class, 2011
    • Chinese University of Hong Kong - Pipeline By Target, 2011
    • Chinese University of Hong Kong - Pipeline By Route of Administration, 2011
    • Chinese University of Hong Kong - Pipeline By Molecule Type, 2011
    • Chinese University of Hong Kong - Dormant Developmental Projects, 2010
    • Chinese University of Hong Kong - Discontinued Pipeline Products, 2010
    • Chinese University of Hong Kong, Other Locations
  • List of Figures
    • Chinese University of Hong Kong - Pipeline by Therapy Area and Indication, 2011
    • Chinese University of Hong Kong - Pipeline by Stage of Development, 2011
    • Chinese University of Hong Kong - Monotherapy Products in Pipeline, 2011
    • Chinese University of Hong Kong - Combination Treatment Modalities in Pipeline, 2011
    • Chinese University of Hong Kong - Pipeline By Therapeutic Class, 2011
    • Chinese University of Hong Kong - Pipeline By Target, 2011
    • Chinese University of Hong Kong - Pipeline By Route of Administration, 2011
    • Chinese University of Hong Kong - Pipeline By Molecule Type, 2011
+44 20 8816 8548

Ask a question about Chinese University of Hong Kong - Developmental Therapeutics Review

Enter the characters you see in the picture below
Captcha